EichorEICHOR
Location: Amberg Synced from ClinicalTrials.gov · August 09, 2026

Clinical studies recruiting near Amberg

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
Phase 2 · Klinikum St. Marien Amberg · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT06722183Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
Phase 3 · Klinikum St. Marien Amberg · AGO Study Group · NCT05009082- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma
Phase 2 · Klinikum St. Marien Amberg · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT06856837Endometrial Cancer Lymphadenectomy Trial
NA · Klinikum St. Marien Amberg, Frauenklinik · Philipps University Marburg · NCT03438474Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Phase 3 · KLINIKUM ST. MARIEN AMBERG - Hämatologie/Onkologie · The Lymphoma Academic Research Organisation · NCT06006117A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic
Phase 3 · Research Site · AstraZeneca · NCT06868277PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
Phase N/A · Klinikum St. Marien Amberg · Women's Cancer Study Group GmbH · NCT05792150A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
Phase N/A · Dr. Med. Thomas Marycz /ID# 274646 · AbbVie · NCT06712628A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in
Phase N/A · Novartis Investigative Site · Novartis Pharmaceuticals · NCT06830720A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With
Phase 3 · Klinikum St. Marien · Hoffmann-La Roche · NCT05894239Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combina
Phase 2/Phase 3 · Klinikum St. Marien Amberg · Mirati Therapeutics Inc. · NCT04613596The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage Hepato
Phase 3 · Klinikum St. Marien Amberg · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT04803994A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Dia
Phase 3 · Research Site · AstraZeneca · NCT07664553PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Dat
Phase N/A · Research Site · AstraZeneca · NCT05573893Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinica
Phase 3 · Klinikum St Marien Amberg Klinik für Frauenheilkunde und Geb · Women's Cancer Study Group GmbH · NCT07242352Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Phase 3 · GESUNDHEITSZENTRUM ST. MARIEN GMBH - Hämatologie/Onkologie · The Lymphoma Academic Research Organisation · NCT06284122A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a
Phase 3 · Research Site · AstraZeneca · NCT07000357EASY Algorithm Trial (Elbow Trauma Assessment Using Sonography in Children and Youth) Diagnostic Accuracy and Safety of
Phase N/A · Klinikum St. Marien Amberg · Timo Munz · NCT07429344A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colo
Phase 3 · Klinikum St. Marien Amberg · Seagen, a wholly owned subsidiary of Pfizer · NCT05253651A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabe
Phase 2 · Versdias - Diabetologikum Amberg · Novo Nordisk A/S · NCT07668388Praegnant Breast Cancer: Early/Advanced/Metastatic
Phase N/A · Gesundheitszentrum St. Marien GmbH · University Hospital Tuebingen · NCT02338167A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisf
Phase N/A · Gesundheitszentrum St. Marien GmbH · Hoffmann-La Roche · NCT06780150Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastat
Phase 4 · Klinikum St. Marien Kommunalunternehmen - AöR Der Stadt Ambe · Prof. Wolfgang Janni · NCT05362760Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Bre
Phase 4 · Klinikum St Marien Amberg · Institut fuer Frauengesundheit · NCT05452213Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
Phase 3 · Klinikum St. Marien Amberg · Dominik Paul Modest · NCT05008809Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Phase 3 · Research Site · AstraZeneca · NCT06677060TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
NA · Klinikum St. Marien Amberg · University Medical Center Nijmegen · NCT04294927A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in
Phase 4 · Versdias - Diabetologikum Amberg · Novo Nordisk A/S · NCT07112339An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
Phase N/A · Dr. Med. Thomas Marycz /ID# 280489 · AbbVie · NCT06764693NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
Phase N/A · Research Site · AstraZeneca · NCT06890273
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.